DEALS

Zhong Lun Advises on Everest Medicines’ IPO in Hong Kong

Release time：2020-10-09 Voice Announcements

On October 9, 2020, Everest Medicines Limited (1952.HK) announced the closing of its initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited, raising the net proceeds of approximately HK$3.28 billion prior to the exercise of the over-allotment option. Goldman Sachs and Merrill Lynch acted as joint sponsors for the offering.

Everest Medicines Limited is a biopharmaceutical company with a focus on developing and commercializing of innovative drugs that integrates licensing, clinical development and commercialization of potentially novel or differentiated therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. As of now, the pipelines of Everest Medicines Limited have covered the areas of oncology, immunology, cardio-renal disease, and infectious disease.

As Everest Medicines Limited’s long-term legal counsel, Zhong Lun Law Firm had provided legal services for its incubation and inception, every round of financing, merger and restructuring, and acted as its PRC legal advisor in this offering. The legal team of Zhong Lun for this offering was led by Anthony Zhao, Catherine Chen, William Jia, and Shaun Gao, and included Roy Zheng, Yun Hu, Lindsay Zhang and etc.; in addition, Mark Gao and Ashley Hu advised on the ESOP tax planning during the IPO process.

Previous：Zhong Lun Assisted Baisheng in Winning Three Patent Infringement Appellate Cases Next：Zhong Lun Advised Nucarf on Strategic Acquisition and PE Financing

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Assists MENA’s First QFII Asset Management Organization to Issue Chinese Securities Product

Zhong Lun Assists Yuan Kee Dumpling with First International Outlet Launch

Events

Awards

Zhong Lun Advises on Everest Medicines’ IPO in Hong Kong